Pablo Velazquez-Martin
Kodiak Sciences Inc
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Pablo Velazquez-Martin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:26 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07734844 · A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTOKodiak Sciences Inc · recruiting · Diabetic Macular Edema (DME) · study director
- Ph3NCT06990399 · A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKKodiak Sciences Inc · recruiting · Macular Edema Secondary to Inflammation · study director
- Ph3NCT06556368 · A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKKodiak Sciences Inc · active not recruiting · Wet Age-related Macular Degeneration · study director
- Ph3NCT06270836 · A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)Kodiak Sciences Inc · completed · Diabetic Retinopathy · study director
- Ph3NCT05066230 · A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)Kodiak Sciences Inc · terminated · Non-proliferative Diabetic Retinopathy · study director
- Ph3NCT04964089 · A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)Kodiak Sciences Inc · completed · Wet Age-related Macular Degeneration · study director
- Ph3NCT04611152 · A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)Kodiak Sciences Inc · terminated · Diabetic Macular Edema · study director
- Ph3NCT04603937 · A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)Kodiak Sciences Inc · terminated · Diabetic Macular Edema · study director
- Ph3NCT04592419 · A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)Kodiak Sciences Inc · completed · Macular Edema, Retinal Vein Occlusion · study director
- Ph2/Ph3NCT04049266 · A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.Kodiak Sciences Inc · terminated · Wet Macular Degeneration · study director
- Ph1NCT03790852 · Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVOKodiak Sciences Inc · terminated · Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.